Stock Research for IPCI

IPCI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IPCI Stock Chart & Research Data

The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IPCI Due diligence Resources & Stock Charts

The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IPCI Detailed Price Forecast - CNN Money CNN View IPCI Detailed Summary - Google Finance
Yahoo View IPCI Detailed Summary - Yahoo! Finance Zacks View IPCI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IPCI Trends & Analysis - Trade-Ideas Barrons View IPCI Major Holders - Barrons
NASDAQ View IPCI Call Transcripts - NASDAQ Seeking View IPCI Breaking News & Analysis - Seeking Alpha
Spotlight View IPCI Annual Report - CompanySpotlight.com OTC Report View IPCI OTC Short Report - OTCShortReport.com
TradeKing View IPCI Fundamentals - TradeKing Charts View IPCI SEC Filings - Bar Chart
WSJ View Historical Prices for IPCI - The WSJ Morningstar View Performance/Total Return for IPCI - Morningstar
MarketWatch View the Analyst Estimates for IPCI - MarketWatch CNBC View the Earnings History for IPCI - CNBC
StockMarketWatch View the IPCI Earnings - StockMarketWatch MacroAxis View IPCI Buy or Sell Recommendations - MacroAxis
Bullish View the IPCI Bullish Patterns - American Bulls Short Pains View IPCI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IPCI Stock Mentions - StockTwits PennyStocks View IPCI Stock Mentions - PennyStockTweets
Twitter View IPCI Stock Mentions - Twitter Invest Hub View IPCI Investment Forum News - Investor Hub
Yahoo View IPCI Stock Mentions - Yahoo! Message Board Seeking Alpha View IPCI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IPCI - SECform4.com Insider Cow View Insider Transactions for IPCI - Insider Cow
CNBC View IPCI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IPCI - OTC Markets
Yahoo View Insider Transactions for IPCI - Yahoo! Finance NASDAQ View Institutional Holdings for IPCI - NASDAQ


Stock Charts

FinViz View IPCI Stock Insight & Charts - FinViz.com StockCharts View IPCI Investment Charts - StockCharts.com
BarChart View IPCI Stock Overview & Charts - BarChart Trading View View IPCI User Generated Charts - Trading View




Latest Financial News for IPCI


Intellipharmaceutics: Fiscal 2Q Earnings Snapshot
Posted on Tuesday July 17, 2018

On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...


Intellipharmaceutics Announces Second Quarter 2018 Results
Posted on Monday July 16, 2018

TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...


Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ
Posted on Friday June 08, 2018

TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.


Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing
Posted on Tuesday May 22, 2018

TORONTO, ON / ACCESSWIRE / May 22, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel granting its request for continued listing until September 28, 2018 while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.